Ikonisys

Ikonisys Financial Leverage

The Financial Leverage (Equity Multiplier) of Ikonisys (ALIKO.PA) as of Nov 5, 2026 is 1.40. In the previous year, Financial Leverage (Equity Multiplier) was 1.92 — a change of -27.36% (lower).

Financial Leverage

1.40

YoY

-27.36%

Last updated:

Financial Leverage (Equity Multiplier) of Ikonisys is 2025 1.40 . Financial Leverage (Equity Multiplier) of Ikonisys was 2024 1.92 . It decreases by -27.36% lower compared to the previous year.

The Ikonisys Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.34 EUR
Jan 1, 2020
1.42 EUR
Jan 1, 2021
1.13 EUR
Jan 1, 2022
1.23 EUR
Jan 1, 2023
1.33 EUR
Jan 1, 2024
1.92 EUR
Jan 1, 2025
1.40 EUR
The Ikonisys Financial Leverage history
YEARFinancial LeverageYoY
1.40-27.36%
1.92+45.04%
1.33+7.86%
1.23+9.21%
1.13-20.68%
1.42+6.22%
1.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ikonisys Stock analysis

What does Ikonisys do? Ikonisys SA generates revenue through the sale of its cell diagnostic products, including oncoFISH bladder, oncoFISH her2, oncoFISH cervical, oncoFISH PTEN, oncoFISH ALK, and Explorer applications. These products are designed for cancer diagnosis, genetic disorder detection, and fertility testing, utilizing advanced molecular and immunological markers. The company's target customers are healthcare providers and clinical laboratories seeking accurate rare cell detection solutions. Ikonisys SA's offerings are tailored to specific medical applications such as bladder, breast, cervical, prostate, lung, and hematological cancer diagnostics, leveraging its proprietary Ikoniscope robotic components and digital microscope technology. The firm's product portfolio focuses on specialized diagnostic applications, with oncoFISH solutions targeting specific cancer types through molecular marker analysis. Explorer applications support hematological cancer diagnostics, while the underlying technology combines image acquisition, software engine, and digital microscopy for reliable cell detection. Ikonisys SA serves the healthcare sector by providing tools that enable precise diagnosis of genetic conditions and cancer types through its unique cellular analysis platform. Ikonisys SA's revenue streams are derived from the distribution of its diagnostic applications to clinical settings. The company's products are sold to healthcare institutions requiring advanced diagnostic capabilities for cancer, genetic disorders, and fertility issues. By offering targeted solutions like oncoFISH bladder for bladder cancer and oncoFISH her2 for breast cancer, Ikonisys SA addresses specific diagnostic needs within the medical field, utilizing its proprietary technology stack including Ikoniscope components and digital microscopy. Ikonisys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ikonisys stock

Financial Leverage (Equity Multiplier) of Ikonisys is 1.40 in 2025.

Financial Leverage (Equity Multiplier) of Ikonisys changed from 1.92 to 1.40, representing a -27.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Ikonisys since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Ikonisys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ikonisys

All Key Metrics — Ikonisys